4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/
(Graphic: Business Wire)
With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.
Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."
This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.
This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.
Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/
Contact information
Press Contacts
Financial Communication and Investor Relations
Jérôme Vailland – Chief Financial Officer
jerome.vailland@4p-pharma.com
Communication – Press Relations
Emmanuel Dadjé - Communication Manager
Emmanuel.dadje@4P-Pharma.com
Tel : +33 6 30 06 12 13
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™ Completes Successful Ischemic Stroke Procedures with the World’s First Robotic Thrombectomy Device15.5.2024 11:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced neurovascular devices, announces the first successful robotic thrombectomy in Medellín, Colombia. Two patients were treated with the Robotic TIGERTRIEVER™, the first endovascular thrombectomy device that adapts autonomously to the patient’s anatomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513456936/en/ The AI-powered TIGERTRIEVER removes stroke-causing blood clots during first-in-man procedures in Colombia. Rapid Medical’s portfolio of active technology allows greater procedural personalization, which is enhanced with AI workflow. (Photo: Business Wire) “Automating stroke procedures is a significant advancement for the medical field,” emphasizes Dr. Boris Pabón, the endovascular neurosurgeon at Angiosur who performed the first-in-man procedures. “Robotic clot removal achieves a level of precision that surpasses interventional capabilities. The robotic TIGERTRIEVER giv
HEINEKEN Teams Up With Blue Yonder To Improve Demand Planning15.5.2024 11:00:00 EEST | Press release
HEINEKEN, the world’s most international brewer, confirms Blue Yonder as a vendor of trust to further transform its supply chain planning capability. The global brewer will implement Blue Yonder Cognitive Demand Planning, a next generation cloud-native, microservices-based SaaS solution, that utilizes artificial intelligence (AI) and machine learning (ML) to improve forecast accuracy and reduce bias by considering dynamic external and internal variables. HEINEKEN has been implementing Blue Yonder solutions for multiple years unlocking value for its business, especially with the potential to improve forecast accuracy through ML demand forecasting solution. HEINEKEN has selected Blue Yonder, as one of the current major supply chain solution providers, to future proof its demand planning process and leverage AI/ML, autonomous scenario planning, planning process orchestration and solution extensibility. “We want to continuously improve our supply chain processes and adopting Blue Yonder Co
Forrester Announces The EMEA Recipient Of Its 2024 Customer-Obsessed Enterprise Award15.5.2024 11:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today announced that Nedbank Retail and Business Banking is the winner of its Europe, Middle East, and Africa (EMEA) 2024 Customer-Obsessed Enterprise Award. The award recognises organisations that are putting customers at the centre of their business strategy to accelerate growth. Nedbank Retail and Business Banking will be honoured at CX Summit EMEA, being held in London and digitally, 24–26 June, 2024. The bank has been selected as the winner for investing in, designing, and delivering a robust customer obsession programme that helps people across the organisation collaborate, focus on what matters most to customers and make CX improvements systematically. “We congratulate Nedbank Retail and Business Banking for winning Forrester’s Customer-Obsessed Enterprise Award in EMEA,” said Martin Gill, vice president and research director at Forrester and host of CX Summit EMEA. “Nedbank Retail and Business Banking is a prime example of how, by nurturing a customer-c
Intergamma and Hanshow Forge Strategic Alliance: Pioneering Digital Retail Solutions in Benelux's DIY Market15.5.2024 11:00:00 EEST | Press release
Hanshow, a global leader in digital retail solutions, has announced its exclusive partnership with Intergamma, the market leader in the Benelux DIY sector, initiating the official installation of Hanshow's Electronic Shelf Labels (ESLs) in November 2023. This collaboration aims to deliver a unique and seamless shopping experience for customers across all channels. This collaboration signals an exciting development in the retail industry as it expands Hanshow's presence in the non-food retail sector with Intergamma operating under the prominent Gamma and Karwei brands, with nearly 400 stores in the Netherlands and Belgium. As of February 2024, installation progress includes the successful completion of ESL deployments in all 128 Karwei stores, with installations for Gamma outlets actively ongoing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240504881462/en/ Hanshow ESLs at Intergamma. (Photo: Business Wire) Joining forces
MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)15.5.2024 10:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy for Inflammatory Bowel Diseases, in two oral presentations during the 2024 Digestive Disease Week® (DDW) meeting, being held May 18-21, 2024 in Washington, D.C. at the Walter E. Washington Convention Center. Late Breaker Presentation Details Session Title: IMIBD Late Breakers and Innovations in IBD Presentation Title: Safety and Efficacy of MH002, an Optimized Live Biotherapeutic Product, for the Treatment of Mild to Moderate Ulcerative Colitis: A First-in-Disease, Double-Blind, Randomized Clinical Trial Presenter: Séverine Vermeire, Ph.D., Principal Investigator and Scientific Advisor of MRM Health Date and Time: Sunday, May 19, 2024, 3:15 PM – 3:30 PM EDT Location: Ballroom B Poster of Distinction Presentation Details Session Title: Microbi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom